Skip to content
  • Partnerships
  • News
  • Contact
Fore Biotherapeutics
  • Pipeline
  • Science
    • Plixorafenib Program
    • Publications
  • Patients
    • Our Science Explained
    • Clinical Trials
    • Forte Trial
    • Expanded Access
  • Company
    • About Us
    • People
    • Leadership
    • Investors
    • Careers
    • Governance
Search
  • Pipeline
  • Science
    • Plixorafenib Program
    • Publications
  • Patients
    • Our Science Explained
    • Clinical Trials
    • Forte Trial
    • Expanded Access
  • Company
    • About Us
    • People
    • Leadership
    • Investors
    • Careers
    • Governance
  • Partnerships
  • News
  • Contact

gRNA Sequence Heterology Tolerance Catalyzed by CRISPR/Cas in an In Vitro Homology-Directed Repair Reaction


June 5, 2020 1:06 PM EDT

Read More

Press Release Jun 03 2020 Novellus Executes Exclusive Worldwide License Agreement with Plexxikon for PLX8394, Plexxikon’s Next-Generation, Clinical StageBRAF Inhibitor Read more
Press Release Jul 20 2017 New partnership between Christiana Care’s Gene Editing Institute and NovellusDx speeds progress toward personalized cancer medicine Read more
Press Release May 22 2017 NovellusDx Registers Another Patent on their FACT™ system,Publishes a New Study With Guardent Health and MD Anderson InCancer Discovery; Was Selected To Present At BioMed, BIO 2017 andASCO Read more
Fore Biotherapeutics logo
  • Science
    • Plixorafenib Program
  • Patients
    • Our Science Explained
    • Clinical Trials
    • Expanded Access
  • Company
    • About Us
    • People
    • Leadership
    • Investors
    • Careers
    • Governance
  • Pipeline
  • Partnerships
  • News
  • Contact
  • Visit us on Twitter
  • Visit us on Linked In
©2025 Fore Biotherapeutics US Inc. All rights reserved.
  • Terms & Conditions
  • Privacy Policy